我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
隶属于 阿斯利康
相关临床试验
3243
2712 进行中
药物批准
340
批准总数
监管机构
6
监管机构数
成立时间
N/A
招募中
422
13.0%
暂停
8
0.3%
撤回
2
0.1%
进行中（未招募）
2655
81.9%
Unknown
11
已完成
81
2.5%
尚未招募
57
1.8%
NMPA
National Medical Products Administration
101
EMA
European Medicines Agency
87
PHILIPPINES
Philippines FDA
18
SFDA
Saudi Food and Drug Authority
31
NPRA
National Pharmaceutical Regulatory Agency
26
CIMA_AEMPS
Spanish Agency for Medicines and Medical Devices
77
- The Health Resources and Services Administration has approved eight pharmaceutical companies to participate in the 340B Rebate Model Pilot Program, which will begin on January 1, 2025. - Nine drugs from major manufacturers including Bristol Myers Squibb's Eliquis, Novo Nordisk's Novolog, and Janssen's Stelara will be included in the voluntary rebate program. - The pilot program allows drugmakers to provide 340B discounted pricing through a rebate model rather than upfront discounts, with HRSA planning to evaluate the program for at least one year. - The initiative follows legal challenges from Johnson & Johnson, Bristol Myers Squibb, and Eli Lilly regarding HRSA's authority to review and approve rebate models in the 340B program.
